Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

→ Build­ing off a sur­prise suc­cess with Mavyret in adults, Ab­b­Vie has nabbed an FDA ap­proval to mar­ket …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.